The predictive value of early molecular response by relative risk in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from the phase 3 DASISION trial

被引：0
|
作者：
Stegelmann, F. [1 ]
Shah, N. P. [2 ]
Saglio, G. [3 ]
Hochhaus, A. [4 ]
Bilmes, R. [5 ]
Li, L. [5 ]
Cortes, J. E. [6 ]
机构：
[1] Univ Klinikum Ulm, Ulm, Germany
[2] UCSF, Sch Med, San Francisco, CA USA
[3] Univ Turin, Turin, Italy
[4] Univ Klinikum Jena, Jena, Germany
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V158
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF DASATINIB IN PATIENTS (PTS) WITH PREVIOUSLY UNTREATED CHRONIC MYELOGENOUS LEUKEMIA (CML) IN EARLY CHRONIC PHASE (CML-CP)
    Cortes, J.
    Borthakur, G.
    Jones, D. M.
    O'Brien, S.
    Koller, C. A.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Kantarjian, H. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 349 - 349
  • [22] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Cortes, Jorge
    O'Brien, Susan
    Jones, Dan
    Koller, Charles
    Borthakur, Gautam
    Nicaise, Claude
    Henderson, Laverne
    Ferrajoli, Alessandra
    Kantarjian, Hagop
    BLOOD, 2007, 110 (11) : 17A - 17A
  • [23] Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP)
    Cortes, Jorge
    Borthakur, Gautam
    O'Brien, Susan
    Jones, Dan
    Jabbour, Elias
    Ravandi, Farhad
    Koller, Charles
    Walker, Brenda
    Shan, Jenny
    Kantarjian, Hagop
    BLOOD, 2009, 114 (22) : 143 - 143
  • [24] Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern
    Cortes, Jorge E.
    Jiang, Qian
    Wang, Jianxiang
    Weng, Jianyu
    Zhu, Huanling
    Liu Xiaoli
    Hochhaus, Andreas
    Kim, Dong-Wook
    Radich, Jerald
    Savona, Michael R.
    Regueira, Patricia Martin
    Sy, Oumar
    Gurnani, Renuka
    Saglio, Giuseppe
    BLOOD, 2018, 132
  • [25] Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP)
    Borthakur, G.
    Kantarjian, H. M.
    O'Brien, S. M.
    Jones, D.
    Koller, C.
    Nicaise, C.
    Garcia-Manero, G.
    Ferrajoli, A.
    Cortes, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] DASATINIB COMPARED TO IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC-PHASE CHRONIC MYELOGENOUS LEUKEMIA (CML-CP): RESULTS FROM THE RANDOMIZED PHASE 3 DASISION TRIA
    Baccarani, M.
    Shah, N.
    Kantarjian, H.
    Cortes, J.
    Shah, S.
    Ayala, M.
    Moiraghi, B.
    Mayer, J.
    Bradley-Garelik, M.
    Zhu, C.
    Hochhaus, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 231 - 231
  • [27] Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib
    Al-Ameri, Ali M.
    Kantarjian, Hagop
    Burton, Elizabeth
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Walker, Brenda
    Rios, Mary Bath
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1275 - 1275
  • [28] Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
    Naqvi, Kiran
    Cortes, Jorge
    Skinner, Jeffrey
    Jabbour, Elias
    Pemmaraju, Naveen
    Borthakur, Gautam
    Estrov, Zeev
    Bose, Prithviraj
    Thompson, Philip
    Kantarjian, Hagop
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (10): : S15 - S16
  • [29] Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd
    Delphine, Rea
    Gautier, Jean-francois
    Breccia, Massimo
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kemp, Charisse
    Gao, Haitao
    Piccolo, Carmen
    Larson, Richard A.
    Hochhaus, Andreas
    BLOOD, 2012, 120 (21)
  • [30] Use of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in chronic phase (CML-CP)
    Atallah, E. L.
    Kantarjian, H.
    O'Brien, S.
    Jones, D.
    Borthakur, G.
    Nicaise, C.
    Cortes, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345